Join our daily newsletter At The Bell to receive exclusive market insights
- Resonance Health (RHT) signs a platform integration and partnership agreement with CARPL.ai
- CARPL.ai is the world’s first testing and deployment platform for medical imaging AI that connects healthcare providers to third-party AI applications
- The agreement allows Resonance to deliver its FerriSmart and HepaFat-AI software medical devices through CARPL.ai’s global installations
- HepaFat-AI measures the volume fraction of fat in liver tissue, while FerriSmart automatically analyses MRI images and returns a liver iron quantification result
- RHT shares steady at 13 cents
Resonance Health (RHT) has entered into a platform integration and partnership agreement with CARPL.ai, which provides a unique platform linking picture archiving and communication systems to artificial intelligence (AI) software medical devices.
The agreement allows Resonance to deliver its FerriSmart and HepaFat-AI software medical devices through CARPL.ai’s global installations.
Resonance said CARPL.ai was the world’s first testing and deployment platform for medical imaging artificial intelligence (AI), connecting healthcare providers to third-party AI applications to help improve access, affordability and quality of medical care.
HepaFat-AI is a non-invasive medical software device that measures the volume fraction of fat in liver tissue and assesses data from magnetic resonance imaging (MRI).
It also assesses the volumetric liver fat fraction, proton density fat fraction and steatosis grade in individuals with confirmed or suspected fatty liver disease.
HepaFat-AI then helps monitor liver fat content in patients undergoing weight loss management and aids in the assessment and screening of living donors for a liver transplant.
FerriSmart automatically analyses MRI images from most scanner makes and models and returns a liver iron quantification result within seconds.
It measures iron concentration in individuals with confirmed or suspected systemic iron overload.
Resonance said the devices would be held in a cloud environment administered and controlled by the company, with de-identified data exchanged between CARPL.ai and Resonance through a secure transfer.
The agreement runs for three years.
“The partnership with CARPL.ai greatly enhances our service delivery into markets such as India, Brazil, USA, Australia, and Canada. We are delighted to work with the highly skilled CARPL.ai team to deliver our AI medical devices to their customers globally,” Managing Director Mitchell Wells said.
“This opportunity also utilises our new delivery methodology for our AI services, which sees us moving away from on-premises deployment to controlled cloud-hosting of our devices.”
RHT shares were steady at 13 cents at 12:28 pm AEST.
